NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

863.15 32.20 (3.88%)

106.64% Gain from 52W Low

2.9M NSE+BSE Volume

NSE 13 Aug, 2025 3:31 PM (IST)

46,595

Market Cap

High in industry

1.2

Beta 1Year

Very High Volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

30 Apr 2021

863.15

3.88%

Laurus Labs

Buy: Laurus Labs Ltd.

Target

ICICI Securities Limited

Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model. Elsewhere, formulations are expected to grow amid ramp up and new launches (e.g. TLE400) in LMIC and launches in the US. Other APIs are expected to be driven by a strong order book and capacity addition. Besides continuous improvement in the financial performances, the company is evolving as a strong vertically integrated player with strong order book visibility, improving margin profile, strengthening return ratios and healthy FCF...

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

30 Jan 2021

863.15

3.88%

Laurus Labs

Buy: Laurus Labs Ltd.

ICICI Securities Limited

Q3 results were above I-direct estimates on all fronts. Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model. Elsewhere, formulations are expected to grow amid ramp up and new launches (e.g. TLE400) in LMIC and launches in the US. Other APIs are expected to be driven by a strong order book and capacity addition. Besides continuous improvement in the financial performances, the company is evolving as a strong vertically integrated player with strong order book visibility, improving margin profile,...

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

29 Jan 2021

863.15

3.88%

Laurus Labs (BUY): Solid margins despite higher API mix TP raised to Rs 480

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported another solid beat in Q3FY21 fuelled by strong growth in the API and synthesis segments.

Laurus Labs Ltd. has gained 45.45% in the last 3 Months

Laurus Labs Ltd.

22 Dec 2020

863.15

3.88%

Laurus Labs

Buy: Laurus Labs Ltd.

Target

Sharekhan

Further, the company's foray in the lucrative biologics/biotech space through the acquisition of a majority stake in Richcore Lifesciences would be a key positive as it would create a new revenue stream. We interacted with the management of Laurus Labs Limited (Laurus) and their commentary suggests a robust growth outlook. Laurus' formulations business is gaining traction with the tender business, which accounts for around three-fourth of total formulation sales, is witnessing sturdy growth. Moreover, Laurus is expanding capacities, primarily through brownfield expansions to cater to increasing demand. The first leg of de-bottlenecking is...

Deven Choksey released a Sell report for Laurus Labs Ltd. with a price target of 640.0 on 01 Aug, 2025.

Laurus Labs Ltd.

26 Nov 2020

863.15

3.88%

Richcore acquisition - A step towards strategic diversification

Buy: Laurus Labs Ltd.

Motilal Oswal

Laurus Labs' (LAURUS) has acquired 73% stake in Richcore Lifesciences (RICH) for a cash consideration of INR2.5b. The acquisition is a step towards building a vertically integrated biotech segment and adds a new lever to growth. It particularly provides capabilities in high growth areas of Recombinant (Rh)...

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

01 Nov 2020

863.15

3.88%

Laurus Labs

Accumulate: Laurus Labs Ltd.

Dolat Capital

Laurus reported robust 2Q beating our estimates primarily driven by stellar growth in formulations. Though majority growth is led by ARV tender based opportunities, leveraging its backward integration, Laurus has demonstrated commendable execution capability as the growth is volume led without any one-offs. Management remained confident of growth sustenance in 2H as well. In order to supplement future growth, Laurus has undertaken a massive capex program (Rs12bn) of which Rs5bn is allocated...

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

30 Oct 2020

863.15

3.88%

Laurus Labs

Buy: Laurus Labs Ltd.

Sharekhan

Synthesis and API segments are on track for a double digit growth. Operating leverage, favorable mix to support OPM expansion. Strong growth prospects, visibility on earnings, healthy balance sheet and return ratios are key positives We retain a Buy recommendation with a revised PT of Rs 385. Q2FY2021 was yet another stellar quarter for Laurus Labs Ltd (Laurus). Sales stood at Rs. 1138.8 crore, translating to a sturdy rise of 60% y-o-y on the back of robust growth in the lucrative formulations business and a double digit growth in the generic API's. Operating margins surprised positively, surging 1351 bps y-o-y to 32.8%, aided by an expansion...